NCT04516447 - A Study of ZN-c3 in Patients With Ovarian Cancer | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2027

Conditions

Solid TumorEpithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer

Interventions

DRUG

ZN-c3

Investigational drug

DRUG

Carboplatin

Carboplatin is an approved drug

DRUG

Pegylated liposomal doxorubicin

Pegylated liposomal doxorubicin (PLD) is an approved drug

DRUG

Paclitaxel

Paclitaxel is an approved drug

DRUG

Gemcitabine

Gemcitabine is an approved drug

BIOLOGICAL

Bevacizumab

Combined with azenosertib

Trial Locations (24)

1632

COMPLETED

Site 1201, Sofia

3121

RECRUITING

Site 2716, Melbourne

3144

RECRUITING

Site 2706, Melbourne

4101

RECRUITING

Site 2707, South Brisbane

4500

COMPLETED

Site 1202, Panagyurishte

4556

RECRUITING

Site 2708, Sunshine Coast

5000

ACTIVE_NOT_RECRUITING

Site 2709, Adelaide

6009

RECRUITING

Site 2705, Nedlands

10029

RECRUITING

Site 0173, New York

11080

COMPLETED

Site 1902, Belgrade

27710

RECRUITING

Site 0259, Durham

37203

COMPLETED

Site 0196, Nashville

53110

RECRUITING

Site 0111, St Louis

71000

COMPLETED

Site 1002, Sarajevo

75000

COMPLETED

Site 1003, Tuzla

77030

RECRUITING

Site 0103, Houston

78000

COMPLETED

Site 1001, Banja Luka

80045

RECRUITING

Site 0264, Aurora

02215

RECRUITING

Site 0104, Boston

02905

RECRUITING

Site 0191, Providence

0112

ACTIVE_NOT_RECRUITING

Site 1401, Tbilisi

Unknown

COMPLETED

Site 2901, Busan

03080

COMPLETED

Site 2903, Seoul

05505

COMPLETED

Site 2904, Seoul

All Listed Sponsors

lead

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

INDUSTRY